InhaleRx Limited (AU:IRX) has released an update.
InhaleRx Ltd has announced positive results from its Phase 1 clinical trial of IRX-211, a non-opioid inhalable analgesic aimed at treating Breakthrough Cancer Pain (BTcP). The study confirmed the drug’s safety and tolerability, paving the way for the upcoming Phase 2 trials to further explore its efficacy. The company highlights the potential of IRX-211 to offer a safer alternative to opioids, with lower risks of addiction and fewer side effects, which could significantly improve patient care and daily activity management.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.
